TABLE OF CONTENTS
1 INTRODUCTION 14
1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 OVERVIEW OF CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET 15
1.4 CURRENCY AND PRICING 17
1.5 LIMITATIONS 17
1.6 MARKETS COVERED 18
2 MARKET SEGMENTATION 21
2.1 MARKETS COVERED 21
2.2 GEOGRAPHICAL SCOPE 22
2.3 YEARS CONSIDERED FOR THE STUDY 23
2.4 DBMR TRIPOD DATA VALIDATION MODEL 24
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 27
2.6 DBMR MARKET POSITION GRID 28
2.7 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET: DBMR VENDOR SHARE ANALYSIS 29
2.8 MULTIVARIATE MODELING 30
2.9 PRODUCT TYPE TIMELINE CURVE 30
2.10 SECONDARY SOURCES 31
2.11 ASSUMPTIONS 31
3 EXECUTIVE SUMMARY 32
4 PREMIUM INSIGHTS 34
5 IMPACT OF COVID-19 ON THE MARKET 35
6 MARKET OVERVIEW 36
6.1 DRIVERS 38
6.1.1 RISING CASES OF CHRONIC DISEASES 38
6.1.2 RISING DEMAND OF SELF-INJECTION DEVICES 39
6.1.3 GROWTH OF BIOLOGICS MARKET 40
6.1.4 TECHNOLOGICAL ADVANCEMENTS AND INNOVATIONS IN DRUG DELIVERY MARKET 41
6.2 RESTRAINTS 42
6.2.1 NEEDLESTICK INJURIES AND INFECTIONS 42
6.2.2 HIGH COST OF DEVELOPMENT 43
6.2.3 STRICT REGULATORY FRAMEWORK 44
?
6.3 OPPORTUNITIES 45
6.3.1 INCREASING DEMAND FOR GENERIC AND BIOSIMILAR DRUGS 45
6.3.1.1 GENERICS 45
6.3.1.2 BIOSIMILARS 45
6.3.2 INCREASING DEMAND FOR SELF-ADMINISTRATION OF DRUGS 46
6.4 CHALLENGES 46
6.4.1 ALTERNATIVE ROUTE OF DRUG ADMINISTRATION 46
6.4.2 PRODUCT RECALL 47
6.4.3 STABILITY OF PRODUCTS 48
6.4.4 STERILITY OF INJECTIONS 48
7 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY PRODUCT TYPE 49
7.1 OVERVIEW 50
7.2 DEVICES 51
7.2.1 CONVENTIONAL INJECTABLE DEVICES 52
7.2.1.1 CONVENTIONAL INJECTABLE DEVICES, BY MATERIAL 53
7.2.1.1.1 GLASS 53
7.2.1.1.2 PLASTIC 54
7.2.1.2 CONVENTIONAL INJECTABLE DEVICES, BY PRODUCT TYPE 54
7.2.1.2.1 FILLABLE 55
7.2.1.2.2 PREFILLED 55
7.2.1.3 CONVENTIONAL INJECTABLE DEVICES, BY USABILITY 56
7.2.1.3.1 DISPOSABLE SYRINGES 56
7.2.1.3.2 REUSABLE SYRINGES 56
7.2.2 NEEDLE-FREE INJECTORS 57
7.2.2.1 NEEDLE-FREE INJECTORS, BY PRODUCT 58
7.2.2.1.1 FILLABLE NEEDLE-FREE INJECTORS 58
7.2.2.1.2 PREFILLED NEEDLE-FREE INJECTORS 58
7.2.2.2 NEEDLE-FREE INJECTORS, BY TECHNOLOGY 58
7.2.2.2.1 JET BASED NEEDLE-FREE INJECTORS 59
7.2.2.2.2 SPRING BASED NEEDLE-FREE INJECTORS 59
7.2.2.2.3 LASER POWERED NEEDLE-FREE INJECTORS 60
7.2.2.2.4 VIBRATION BASED NEEDLE-FREE INJECTORS 60
7.2.2.3 NEEDLE-FREE INJECTORS, BY USABILITY 61
7.2.2.3.1 DISPOSABLE NEEDLE-FREE INJECTORS 61
7.2.2.3.2 REUSABLE NEEDLE-FREE INJECTORS 61
7.2.3 AUTO INJECTORS 62
7.2.3.1 AUTO INJECTORS, BY PRODUCT 62
7.2.3.1.1 FILLABLE AUTO INJECTORS 62
7.2.3.1.2 PRE-FILLED AUTO INJECTORS 63
?
7.2.3.2 AUTO INJECTORS, BY TECHNOLOGY 63
7.2.3.2.1 AUTOMATED AUTO INJECTORS 64
7.2.3.2.2 MANUAL AUTO INJECTORS 64
7.2.3.3 AUTO INJECTORS, BY DESIGN 64
7.2.3.3.1 STANDARDIZED AUTO INJECTORS 64
7.2.3.3.2 CUSTOMIZED AUTO INJECTORS 65
7.2.3.4 AUTO INJECTORS, BY USABILITY 65
7.2.3.4.1 DISPOSABLE AUTO INJECTORS 65
7.2.3.4.2 REUSABLE AUTO INJECTORS 66
7.2.4 PEN INJECTORS 66
7.2.4.1 PEN INJECTORS, BY PRODUCT 67
7.2.4.1.1 SINGLE CHAMBERED PEN INJECTORS 67
7.2.4.1.2 DUAL CHAMBERED PEN INJECTORS 67
7.2.4.2 PEN INJECTORS, BY DESIGN 68
7.2.4.2.1 STANDARDIZED PEN INJECTORS 68
7.2.4.2.2 CUSTOMIZED PEN INJECTORS 68
7.2.4.3 PEN INJECTORS, BY USABILITY 69
7.2.4.3.1 DISPOSABLE PEN INJECTORS 69
7.2.4.3.2 REUSABLE PEN INJECTORS 69
7.2.5 WEARABLE INJECTORS 69
7.2.6 OTHERS 70
7.3 FORMULATION 70
7.3.1 NOVEL DRUG DELIVERY FORMULATIONS 71
7.3.1.1 COLLOIDAL DISPERSIONS 72
7.3.1.1.1 NIOSOMES 73
7.3.1.1.2 LIPOSOMES 73
7.3.1.1.3 POLYMERIC MIXED MICELLES 74
7.3.1.1.4 NANOPARTICLES 75
7.3.1.1.5 SOLID LIPID NANOPARTICLES 76
7.3.1.1.5.1 NANOSUSPENSIONS 77
7.3.1.1.5.2 NANOEMULSIONS/MICROEMULSIONS 77
7.3.1.2 MICROPARTICLES 78
7.3.1.2.1 MICROSPHERES 78
7.3.1.2.2 MICROCAPSULES 79
7.3.2 CONVENTIONAL DRUG DELIVERY FORMULATIONS 80
7.3.2.1 SOLUTIONS 80
7.3.2.2 RECONSTITUTED/LYOPHILIZED FORMULATIONS 81
7.4 LIST OF SOME OF THE LYOPHILIZED FORMULATIONS 81
7.4.1.1 SUSPENSIONS 82
7.4.1.2 EMULSIONS 82
7.5 LIST OF SOME OF THE EMULSIONS 83
7.5.1 LONG ACTING FORMULATIONS 83
7.6 LIST OF SOME OF THE FIRST GENERATION LONG ACTING INJECTION 84
7.7 LIST OF SOME OF THE SECOND GENERATION LONG ACTING INJECTION: 84
8 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY APPLICATION 85
8.1 OVERVIEW 86
8.2 HORMONAL DISORDERS 87
8.3 DIABETES 88
8.3.1 ANTITHROMBOTIC/THROMBOLYTIC THERAPY 89
8.3.2 ANEMIA 90
8.3.3 REPRODUCTIVE HEALTH DISEASE 91
8.3.4 OSTEOPOROSIS 92
8.3.5 GROWTH HORMONE DEFICIENCY 93
8.4 ONCOLOGY 93
8.5 AUTOIMMUNE DISORDERS 94
8.5.1 RHEUMATOID ARTHRITIS 95
8.5.2 MULTIPLE SCLEROSIS 96
8.5.3 CROHN'S DISEASES 97
8.5.4 PSORIASIS 98
8.5.5 OTHER AUTOIMMUNE DISEASE 99
8.6 ORPHAN DISEASE 99
8.7 OTHER 100
8.7.1 ALLERGY 100
8.7.2 PAIN MANAGEMENT 101
8.7.3 HEPATITIS C 102
8.7.4 AESTHETIC TREATMENTS 103
8.7.5 HEMOPHILIA 104
9 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY USAGE PATTERN 105
9.1 OVERVIEW 106
9.2 CURATIVE CARE 107
9.3 IMMUNIZATIONS 108
9.4 OTHER USAGE PATTERN 109
10 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY MODE OF ADMINISTRATION 110
10.1 OVERVIEW 111
10.2 SKIN 112
10.3 CIRCULATORY/MUSCULOSKELETAL 113
10.4 ORGANS 114
10.5 CENTRAL NERVOUS SYSTEM 114
11 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY END USER 116
11.1 OVERVIEW 117
11.2 HOSPITALS AND CLINICS 118
11.3 HOME HEALTHCARE SETTINGS 119
11.4 RESEARCH LABORATORIES 119
11.5 PHARMACEUTICAL AND BIOTECHNOLOGICAL COMPANIES 119
11.6 OTHERS 120
12 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, BY DISTRIBUTION CHANNEL 121
12.1 OVERVIEW 122
12.2 DIRECT TENDER 123
12.3 HOSPITAL PHARMACY 123
12.4 PHARMACY STORES 124
12.5 ONLINE PHARMACY 124
13 CHINA INJECTABLE DRUG DELIVERY DEVICES MARKET, COMPANY LANDSCAPE 125
13.1 COMPANY SHARE ANALYSIS: CHINA 125
14 SWOT & DATA BRIDGE MARKET RESEARCH ANALYSIS 126
14.1 STRENGTH: - DIVERSE PRODUCT PORTFOLIO 126
14.2 STRENGTH: - DIVERSIFIED GEOGRAPHIC PRESENCE 127
14.3 WEAKNESS: - PRODUCT RECALLS 128
14.4 OPPORTUNITY: - PRODUCT LAUNCHES 128
14.5 OPPORTUNITY: - STRATEGIC DECISIONS 129
14.6 THREAT: - GOVERNMENT REGULATION 130
15 COMPANY PROFILE 131
15.1 PFIZER INC. 131
15.1.1 COMPANY SNAPSHOT 131
15.1.2 REVENUE ANALYSIS 132
15.1.3 PRODUCT PORTFOLIO 133
15.1.4 RECENT DEVELOPMENTS 134
15.2 SHANGHAI FOSUN PHARMACEUTICAL(GROUP)CO., LTD. 135
15.2.1 COMPANY SNAPSHOT 135
15.2.2 REVENUE ANALYSIS 136
15.2.3 PRODUCT PORTFOLIO 136
15.2.4 RECENT DEVELOPMENT 137
?
15.3 NOVO NORDISK A/S 138
15.3.1 COMPANY SNAPSHOT 138
15.3.2 REVENUE ANALYSIS 139
15.3.3 PRODUCT PORTFOLIO 139
15.3.4 RECENT DEVELOPMENT 140
15.4 BD 141
15.4.1 COMPANY SNAPSHOT 141
15.4.2 REVENUE ANALYSIS 142
15.4.3 PRODUCT PORTFOLIO 142
15.4.4 RECENT DEVELOPMENTS 143
15.5 BAXTER 145
15.5.1 COMPANY SNAPSHOT 145
15.5.2 REVENUE ANALYSIS 146
15.5.3 PRODUCT PORTFOLIO 146
15.5.4 RECENT DEVELOPMENTS 147
15.6 CHANGEE MEDICAL DEVICES CO., LTD 148
15.6.1 COMPANY SNAPSHOT 148
15.6.2 PRODUCT PORTFOLIO 148
15.6.3 RECENT DEVELOPMENT 149
15.7 CHINA MEHECO GROUP CO., LTD. 150
15.7.1 COMPANY SNAPSHOT 150
15.7.2 PRODUCT PORTFOLIO 150
15.7.3 RECENT DEVELOPMENT 150
15.8 ELCAM MEDICAL 151
15.8.1 COMPANY SNAPSHOT 151
15.8.2 PRODUCT PORTFOLIO 151
15.8.3 RECENT DEVELOPMENT 151
15.9 ELI LILLY AND COMPANY 152
15.9.1 COMPANY SNAPSHOT 152
15.9.2 REVENUE ANALYSIS 153
15.9.3 PRODUCT PORTFOLIO 153
15.9.4 RECENT DEVELOPMENT 153
15.10 GERRESHEIMER AG 154
15.10.1 COMPANYSNAPSHOT 154
15.10.2 REVENUE ANALYSIS 155
15.10.3 PRODUCT PORTFOLIO 156
15.10.4 RECENT DEVELOPMENT 156
15.11 HARBIN PHARMACEUTICAL GROUP CO., LTD. 157
15.11.1 COMPANY SNAPSHOT 157
15.11.2 PRODUCT PORTFOLIO 157
15.11.3 RECENT DEVELOPMENT 157
15.12 HENGRUI MEDICINE 158
15.12.1 COMPANY SNAPSHOT 158
15.12.2 PRODUCT PORTFOLIO 158
15.12.3 RECENT DEVELOPMENTS 159
15.13 JIANGSU DELFU MEDICAL DEVICE CO., LTD 160
15.13.1 COMPANY SNAPSHOT 160
15.13.2 PRODUCT PORTFOLIO 160
15.13.3 RECENT DEVELOPMENT 162
15.14 MYLAN N.V. 163
15.14.1 COMPANY SNAPSHOT 163
15.14.2 REVENUE ANALYSIS 164
15.14.3 PRODUCT PORTFOLIO 164
15.14.4 RECENT DEVELOPMENT 164
15.15 SANDOZ INTERNATIONAL GMBH 165
15.15.1 COMPANY SNAPSHOT 165
15.15.2 REVENUE ANALYSIS 166
15.15.3 PRODUCT PORTFOLIO 166
15.15.4 RECENT DEVELOPMENTS 167
15.16 SANOFI 168
15.16.1 COMPANY SNAPSHOT 168
15.16.2 REVENUE ANALYSIS 169
15.16.3 PRODUCT PORTFOLIO 169
15.16.4 RECENT DEVELOPMENTS 170
15.17 SCHOTT AG 171
15.17.1 COMPANY SNAPSHOT 171
15.17.2 PRODUCT PORTFOLIO 171
15.17.3 RECENT DEVELOPMENTS 172
15.18 SHANGHAI GENERAL PHARMACEUTICAL CO., LTD 173
15.18.1 COMPANY SNAPSHOT 173
15.18.2 PRODUCT PORTFOLIO 173
15.18.3 RECENT DEVELOPMENT 173
15.19 TERUMO CORPORATION 174
15.19.1 COMPANY SNAPSHOT 174
15.19.2 REVENUE ANALYSIS 175
15.19.3 PRODUCT PORTFOLIO 176
15.19.4 RECENT DEVELOPMENTS 176
?
15.20 WEST PHARMACEUTICAL SERVICES, INC. 177
15.20.1 COMPANY SNAPSHOT 177
15.20.2 REVENUE ANALYSIS 178
15.20.3 PRODUCT PORTFOLIO 178
15.20.4 RECENT DEVELOPMENTS 179
15.21 YPSOMED 180
15.21.1 COMPANY SNAPSHOT 180
15.21.2 REVENUE ANALYSIS 181
15.21.3 PRODUCT PORTFOLIO 182
15.21.4 RECENT DEVELOPMENT 182
15.22 SHANGHAI UMITAI MEDICAL TECHNOLOGY CO.,LTD. 183
15.22.1 COMPANY SNAPSHOT 183
15.22.2 PRODUCT PORTFOLIO 184
15.22.3 RECENT DEVELOPMENT 185
16 CONCLUSION 186
17 RELATED REPORTS 187